Individuals with cystic fibrosis — adults as well infants and children — have long struggled to gain and maintain their weight. But how has the current widespread use of highly effective modulator treatments — HEMT — changed that situation? That’s the focus of this eCysticFibrosis Review Special Edition: CF and Nutrition and HEMT.  The first part o…

The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? Join us as we explore these questions with guest autho…

Managing pulmonary exacerbations in people with cystic fibrosis: is there high-grade evidence to support best practices? How helpful is the most current guidance? Does the recent research challenge the current standard of care? Join us for this eCysticFibrosis Review podcast, as Dr. D.B. Sanders from the Indiana University School of Medicine explai…

Race and ethnicity. How do they affect a patient’s ability to receive a timely and accurate cystic fibrosis diagnosis? How do the social determinants of health limit access to appropriate CF treatment and produce poorer outcomes? That’s what we’re here to talk about today with Dr. Jennifer Taylor-Cousar from National Jewish Health and Children’s Ho…

Pancreatic insufficiency. In children with CF, it’s been associated with delayed development and increased odds of developing severe lung disease. How can it be more accurately diagnosed? And what does the evidence say about the effects of treatment with CFTR modulators? That’s what we explore in this case-based podcast, with Dr. Vikesh Singh, Asso…

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…

Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their pa…

Studies have shown that adolescent and young adult women with cystic fibrosis often turn to their CF care team for answers to their questions about their sexual and reproductive health. But how prepared are CF clinicians to initiate conversations? Do they have the most current data about pregnancy decisions for women taking CFTR modulators? When sh…

Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what …

No-contact telemedicine to better protect CF clinic patients and staff during this pandemic may sound like a great idea, but is it even possible to institute? In this eCysticFibrosis Review Special Edition podcast, we find out how pulmonary and critical care specialists Dr. Dana Albon and Dr. Lindsay Somerville successfully brought telemedicine to …

Where, beyond the lungs, do CFTR modulators provide beneficial effects? Can treatment promote growth in height and BMI? What’s known about CFTR modulator effects on cystic fibrosis-associated liver disease? In this eCysticFibrosis Review podcast, Drs. Darla Shores and Anna Reed from the THRIVE Pediatric Intestinal Rehabilitation Center in the Divis…

Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who’s most likely to receive them? In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s A…

Anxiety and depression in cystic fibrosis — who do these conditions affect? How much do they influence patient health? How can clinicians identify and manage them? What evidence-based interventions have been shown to work? In this issue, Dr. Anna Georgiopoulos, Assistant Professor of Psychiatry, Part-Time, Harvard Medical School and Consulting Psyc…

New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung? In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies. Take our post-test to claim CME credits. To read a companion newsletter click he…

Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents? Which medications are appropriate fo…

The effects of CFTR modifiers on improving lung function in people with cystic fibrosis are well known. But what about their effects on the GI tract that directly affect nutrition? In this issue, Dr. Michael Wilschanski — Director of Hadassah Hospital’s Pediatric Gastroenterology Unit at Hebrew University in Jerusalem — explains how new findings ab…

Volume 8, Issue 7. Part 3 Hosted on Acast. See acast.com/privacy for more information.

Volume 8, Issue 7. Part 2 Hosted on Acast. See acast.com/privacy for more information.

Volume 8, Issue 7. Part 1 Hosted on Acast. See acast.com/privacy for more information.

In this issue, Dr. Gregory Sawicki — Associate Professor of Pediatrics at Harvard Medical School and Director of the Cystic Fibrosis Center at Boston Children’s Hospital — discusses how the recent findings about the real-world use of CFTR modulators can impact clinical practice. Take our post-test to claim CME credits. To read a companion newslette…

Multidrug resistant lung infections present an increasingly common and increasingly dangerous threat to all individuals with cystic fibrosis. Common CF pathogens — Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter xylosoxidans, Stenotrophomonas maltophilia — are all showing increasing resistance to clinicians’ usual antibiotic arm…

Screening to avoid the morbidity and mortality of colorectal cancer (CRC) in patients with CF, with the incidence of CRC rising, has become an increasingly important challenge, particularly among lung transplant patients. But how and when should patients be screened? With colonoscopy or non-invasive FIT? Before or after transplant? Are there patien…

Volume 7, Issue 12. In this podcast Dr. John P. Clancy reviews CFTR modulators, and discusses insights presented at the 2017 NACFC. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post CFTR Modulators: Clinical Insights appeared first on DKBmed Radio. Hosted on Acast. See a…

Volume 7, Issue 10. In this podcast Andrea Granados, MD describes the clinical impact of the early diagnosis of glucose abnormalities in people with CF, summarizes the limitations of alternative modalities for screening and diagnosing CFRD, and and identifies the current recommendations for the management of CFRD. Take our post-test to claim CME cr…

Volume 7, Issue 8. In this podcast Dr. George Solomon discusses new directions in CFTR modification in the context of case studies. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post New Directions in CFTR Modification appeared first on DKBmed Radio. Hosted on Acast. See …

Volume 7, Issue 6. Our guest author is Amanda Leonard, MPH, RD, CDE, from the Johns Hopkins Children's Hospital in Baltimore, MD. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Nutritional Management for Individuals with CF: Practical Applications appeared first on DK…

Volume 7, Issue 4. Our guest author is Gregory Sawicki, MD, MPH from Boston Children's Hospital, and Harvard Medical School in Boston, MA. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Adherence – What You Should be Telling Your Patients appeared first on DKBmed Radi…

Volume 7, Issue 2. Our guest authors are Mark T. Jennings, MD, MHS and Rebecca Dezube, MD from the Johns Hopkins University School of Medicine in Baltimore, MD. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Weighing the Options in Managing Exacerbations appeared firs…

Volume 6, Issue 12. Claire Wainwright, FRACP, MD and Tonia Douglas, MD cover the important topic of the Future Landscape of CFTR Modulators in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Future Landscape…

Volume 6, Issue 10. Christopher Oermann, MD covers the important topic of the Pseudomonas Eradication in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Pseudomonas aeruginosa Eradication and Outcomes: Key Q…

Volume 6, Issue 8. Dr. Deepak Agrawal, MD covers the important topic of Nutritional Issues in Cystic Fibrosis in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Nutritional Issues in Cystic Fibrosis appeared…

Volume 6, Issue 6. Daniel Heintz, MD and Karen McCoy, MD cover the important topic of Trends in Inhaled Antibiotic Therapy in the format of case-study scenarios for the clinical practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Trends in Inhaled Antibiotic Ther…

Volume 6, Issue 4. Our guest author is John J. LiPuma from the University of Michigan in Ann Arbor, Michigan. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click here. The post Pulmonary Exacerbations and the Microbiology of the CF Lung appeared first on DKBmed Radio. Hosted on Acast. Se…

Volume 6, Issue 2. In this issue we are joined by one of our Program Directors, Dr. Noah Lechtzin from the Johns Hopkins University. Dr. Lechtzin will address the current state of CFTR modification and how it can be applied in practice. Take our post-test to claim CME credits: Physician post-test Nurse post-test To read a companion newsletter click…

Special Edition 2015, Part 4. Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Stuart Elborn of Queen's University in Belfast, Ireland. Dr. Elborn discusses the implications of the CAT study and how it effects his practice. The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast…

Special Edition 2015, Part 3. Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. JP Clancy of Cincinnati Children's Hospital. Dr. Clancy discusses the implications of the CAT study and how it effect his practice. The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on Acast. See acast.c…

Special Edition 2015, Part 2. Join us as Dr. Patrick Flume of the Medical University of South Carolina interviews Dr. Scott Bell of the QIMR Berghofer Medical Research Institute. Dr. Bell discusses the implications of the CAT study and how it will effect his practice. The post Breaking Coverage of CAT trial appeared first on DKBmed Radio. Hosted on…

Special Edition 2015, Part 1. Join us as Dr. Peter Mogayzel of the Johns Hopkins University discusses the design and findings for the CAT study with Dr. Patrick Flume of the Medical University of South Carolina. Learn about the importance of the study and how it may effect your practice. The post Breaking Coverage of CAT trial appeared first on DKB…

Volume 5, Issue 14. In this issue we are joined by Dr. Shawn Aaron of University of Ottawa in Ontario, Canada. Dr. Aaron will discuss infection in patients with optimal therapy of chronic Pseudomonas aeruginosa cystic fibrosis, describe the pathophysiology of pulmonary exacerbations associated with Pseudomonas infection in patients with cystic fibr…

Volume 5, Issue 12. In this issue of eCysticfibrosis Review Dr. Chris Goss of the University of Washington Medical Center. Dr. Goss discusses the benefits of CFTR modification beyond Fev1 improvement through the use of patient-cases. The post Benefits of CFTR Modification Beyond FEV1 Improvement appeared first on DKBmed Radio. Hosted on Acast. See …

Volume 5, Issue 10. In this issue of eCystifibrosis Review we will be join by Dr. Stuart Elborn of Queens University in Belfast, Northern Ireland. Dr. Elborn discusses the effects of CFTR-Modifying Therapies. He will present three patient-case scenarios and identify appropriate treatment options. The post The Effects of CFTR-modifying Therapies app…

Volume 5, Issue 8. In this issue of eCysticFibrosis Review Dr. John Pohl discuses how to optimize nutrition in individuals with CF. Through patient case-scenarios he applies best practices to achieve optimal nutrition using PERT dosing. The post Optimizing Nutrition in Individuals with Cystic Fibrosis appeared first on DKBmed Radio. Hosted on Acast…

Volume 5, Issue 6. In this issue Dr. Steven Freedman, Professor of Medicine from Harvard Medical School discusses digestive capabilities in nutritionally compromised patients with CF. Listen in as Dr. Freedman explains the importance of pancreatic enzyme replacement and present patient scenarios and best practices of treatment. The post Improving d…

Volume 5, Issue 4. In this issue of eCysticfibrosis Review Dr. Ratjen discusses the challenges of P. aeruginosa eradication. He explains the importance to treat early and available treatment options. He also addresses whether treatment should be repeated in patients who develop recurrence of infection and how to handle patients failing eradication …

Volume 5, Issue 2. In this podcast Dr. Patrick Flume, Professor of Medicine and Pediatrics at the Medical University of South Carolina in Charleston, discusses pulmonary exacerbation. He provides patient case scenarios to understand the importance of pulmonary exacerbation and the ability to identify when it occurs. The post Pulmonary exacerbations…

Volume 4, Issue 12. In this issue our guest author is Dr. Patrick Sosnay, Assistant Professor at the Johns Hopkins Cystic Fibrosis Center. Dr. Sosnay will illustrate how the genetics of CF can be used to make a diagnosis or identify a CF carrier, predict how individuals with a given mutation will do clinically and allow clinicians to select current…

Volume 4, Issue 10. In this podcast we have guest author Lori Stark, PhD, ABPP, Professor of Pediatrics at the University of Cincinnati College of Medicine. Dr. Stark, discusses how to use “shaping” to encourage a child to eat a non-preferred food, describes the role of “attention” in maintaining behaviors incompatible with eating, and discusses th…

Special Edition 2014 – Steven Rowe. In this special edition of eCysticFibrosis Review, Dr. Peter Mogayzel discusses data findings from Dr. Steven Rowe results of the G551D observational study presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah. The post Highlights of the 27th Annual North American Cystic F…